Outcomes of Patients Who Are BCMA (B-cell maturation Antigen) Directed Therapy (BDT) Exposed Vs BCMA Naive in Penta-Relapsed Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Mammadzadeh, Aytaj [1 ]
Peng, Fulei [2 ]
Atrash, Shebli [3 ,4 ]
Hashmi, Hamza [3 ,5 ]
Mohan, Meera [3 ,6 ]
Alkharabsheh, Omar [3 ,7 ]
Afrough, Aimaz [3 ,8 ]
Cui, Wei [3 ,9 ]
Mahmoudjafari, Zahra [3 ,10 ]
Abdallah, Al-Ola [11 ,12 ]
机构：
[1] Azerbaijan Med Univ, Dept Internal Med, Baku, Azerbaijan
[2] Mercy St Louis Hosp, Dept Internal Med, St Louis, MO USA
[3] US Myeloma Res Innovat Res Collaborat USMIRC, Westwood, KS USA
[4] Atrium Hlth, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA
[5] Med Univ South Carolina, Dept Hematol Med Oncol, Charleston, SC 29425 USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Univ S Alabama, Mitchell Canc Inst, Div Hematol Oncol, Mobile, AL USA
[8] UT Southwestern Med Ctr, Div Hematol Malignancies & Cellular Therapy, Dept Internal Med, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA
[9] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
[10] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Kansas City, KS 66103 USA
[11] Univ Kansas, Med Ctr, Div Hematol Malignancies & Cellular Therapeut, Westwood, KS USA
[12] US Myeloma Innovat Res Collaborat USMIRC, Westwood, KS USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-165762
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4277 / 4278
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetics and Immunogenicity of Abbv-383, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific T-Cell-Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Polepally, Akshanth R.
    Biesdorf, Carla
    Uddin, Muhammad Erfan
    Boehm, Nils
    Ross, Jeremy A.
    Kumar, Shaji Kunnathu
    Voorhees, Peter M.
    D'Souza, Anita
    Weisel, Katja
    Bueno, Orlando
    Talati, Chetasi
    Menon, Rajeev M.
    BLOOD, 2023, 142
  • [32] BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
    Fang, Jiamin
    Zhou, Fuling
    ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1069 - 1083
  • [33] Beyond BCMA: Outcomes of relapsed/refractory multiple myeloma after progression on anti-BCMA T cell redirecting therapy.
    Arora, Sankalp
    Giri, Smith
    Godby, Kelly Nicole
    Ravi, Gayathri
    Costa, Luciano J.
    Bal, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [34] B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
    Shah, Nina
    Chari, Ajai
    Scott, Emma
    Mezzi, Khalid
    Usmani, Saad Z.
    LEUKEMIA, 2020, 34 (04) : 985 - 1005
  • [35] B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
    Nina Shah
    Ajai Chari
    Emma Scott
    Khalid Mezzi
    Saad Z. Usmani
    Leukemia, 2020, 34 : 985 - 1005
  • [36] Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)
    Cohen, Adam D.
    Garfall, Alfred L.
    Stadtmauer, Edward A.
    Lacey, Simon F.
    Lancaster, Eric
    Vogl, Dan T.
    Weiss, Brendan M.
    Ambrose, David E.
    Nelson, Anne Marie
    Chen, Fang
    Plesa, Gabriela
    Kulikovskaya, Irina
    Gonzalez, Vanessa
    Gupta, Minnal
    Young, Regina M.
    Dengel, Karen
    O'keefe, Laura
    Le, Samantha
    Richardson, Celeste
    Isaacs, Randi E.
    Melenhorst, J. Joseph
    Levine, Bruce L.
    June, Carl H.
    Milone, Michael C.
    BLOOD, 2017, 130
  • [37] A Novel Composite Endpoint of Toxicity- and Progression-Free Survival after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Mohty, Razan
    Junmin, Whiting
    Saha, Aditi
    Kim, Jongphil
    Nishihori, Taiga
    De Avila, Gabriel
    Corallo, Salvatore
    Dam, Marian
    Marin, Jessica
    Liu, Hien
    Mokhtari, Sepideh
    Jain, Michael D.
    Perna, Fabiana
    Blue, Brandon
    Grajales-Cruz, Ariel F.
    Castaneda, Omar
    Shain, Kenneth
    Baz, Rachid
    Freeman, Ciara Louise L.
    Alsina, Melissa
    Locke, Frederick L.
    Hansen, Doris K.
    Lazaryan, Aleksandr
    BLOOD, 2023, 142
  • [38] Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
    Nooka, Ajay K.
    Moreau, Philippe
    Usmani, Saad Zafar
    Garfall, Alfred L.
    Van De Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Oriol Rocafiguera, Albert
    Chari, Ajai
    Karlin, Lionel
    Mateos, Maria-Victoria
    Popat, Rakesh
    Martinez, Joaquin
    Sidana, Surbhi
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Uhlar, Clarissa
    Stephenson, Tara
    Banerjee, Arnob
    Krishnan, Amrita Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
    Al Hadidi, Samer
    Szabo, Aniko
    Esselmann, Jean
    Hammons, Lindsay
    Hussain, Munawwar
    Ogunsesan, Yetunde
    Thalambedu, Nishanth
    Khan, Fatima
    Sethi, Jaskirat
    Janardan, Abhishek
    Radhakrishnan, Sabarinath
    Thanendrarajan, Sharmilan
    Schinke, Carolina
    Dhakal, Binod
    Janz, Siegfried
    Chhabra, Saurabh
    D'Souza, Anita
    Zangari, Maurizio
    van Rhee, Frits
    Mohan, Meera
    BLOOD, 2022, 140 : 8038 - 8039
  • [40] Ciltacabtagene autoleucel CAR-T therapy targeting B-cell maturation antigen (BCMA) Treatment of multiple myeloma
    Lee, Sarah
    Cowan, Andrew J.
    DRUGS OF THE FUTURE, 2022, 47 (04) : 233 - 238
12345